Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests

被引:73
作者
Burdi, Rosa [1 ]
Rolland, Jean-Francois [1 ]
Fraysse, Bodvael [1 ]
Litvinova, Karina [1 ]
Cozzoli, Anna [1 ]
Giannuzzi, Viviana [1 ]
Liantonio, Antonella [1 ]
Camerino, Giulia Maria [1 ]
Sblendorio, Valeriana [1 ,2 ]
Capogrosso, Roberta Francesca [1 ]
Palmieri, Beniamino [2 ]
Andreetta, Francesca [3 ]
Confalonieri, Paolo [3 ]
De Benedictis, Leonarda [4 ,5 ]
Montagnani, Monica [4 ,5 ]
De Luca, Annamaria [1 ]
机构
[1] Univ Bari, Fac Pharm, Dept Pharmacobiol, Pharmacol Unit, Bari, Italy
[2] Univ Modena, Dept Gen Surg & Surg Specialties, I-41100 Modena, Italy
[3] Natl Neurol Inst Carlo Besta, Muscular Pathol Unit, Milan, Italy
[4] Univ Bari, Sch Med, Dept Pharmacol, Bari, Italy
[5] Univ Bari, Sch Med, Dept Human Physiol, Bari, Italy
关键词
muscular dystrophy; preclinical test; calcium homeostasis; oxidative stress; exercise; phosphodiesterase inhibitors; SKELETAL-MUSCLE; OXIDATIVE STRESS; CALCIUM INFLUX; MOUSE MODEL; REGENERATION; ACTIVATION; DIAPHRAGM; PATHWAY; FIBERS; CELLS;
D O I
10.1152/japplphysiol.90985.2008
中图分类号
Q4 [生理学];
学科分类号
071003 [生理学];
摘要
Burdi R, Rolland JF, Fraysse B, Litvinova K, Cozzoli A, Giannuzzi V, Liantonio A, Camerino GM, Sblendorio V, Capogrosso RF, Palmieri B, Andreetta F, Confalonieri P, De Benedictis L, Montagnani M, De Luca A. Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests. J Appl Physiol 106: 1311-1324, 2009. First published January 8, 2009; doi:10.1152/japplphysiol.90985.2008.-The phosphodiesterases inhibitor pentoxifylline gained attention for Duchenne muscular dystrophy therapy for its claimed anti-inflammatory, antioxidant, and antifibrotic action. A recent finding also showed that pentoxifylline counteracts the abnormal overactivity of a voltage-independent calcium channel in myofibers of dystrophic mdx mice. The possible link between workload, altered calcium homeostasis, and oxidative stress pushed toward a more detailed investigation. Thus a 4- to 8-wk treatment with pentoxifylline (50 mg . kg(-1) . day(-1) ip) was performed in mdx mice, undergoing or not a chronic exercise on treadmill. In vivo, the treatment partially increased forelimb strength and enhanced resistance to treadmill running in exercised animals. Ex vivo, pentoxifylline restored the mechanical threshold, an electro-physiological index of calcium homeostasis, and reduced resting cytosolic calcium in extensor digitorum longus muscle fibers. Mn quenching and patch-clamp technique confirmed that this effect was paralleled by a drug-induced reduction of membrane permeability to calcium. The treatment also significantly enhanced isometric tetanic tension in mdx diaphragm. The plasma levels of creatine kinase and reactive oxygen species were both significantly reduced in treated-exercised animals. Dihydroethidium staining, used as an indicator of reactive oxygen species production, showed that pentoxifylline significantly reduced the exercise-induced increase in fluorescence in the mdx tibialis anterior muscle. A significant decrease in connective tissue area and profibrotic cytokine transforming growth factor-beta(1) was solely found in tibialis anterior muscle. In both diaphragm and gastrocnemius muscle, a significant increase in neural cell adhesion molecule-positive area was instead observed. This data supports the interest toward pentoxifylline and allows insight in the level of cross talk between pathogenetic events in workloaded dystrophic muscle.
引用
收藏
页码:1311 / 1324
页数:14
相关论文
共 49 条
[1]
How calcium influx through calcium leak channels is responsible for the elevated levels of calcium-dependent proteolysis in dystrophic myotubes [J].
Alderton, JM ;
Steinhardt, RA .
TRENDS IN CARDIOVASCULAR MEDICINE, 2000, 10 (06) :268-272
[2]
Immunomodulation of TGF-beta1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: Implications for antifibrotic therapy [J].
Andreetta, Francesca ;
Bernasconi, Pia ;
Baggi, Fulvio ;
Ferro, Paolo ;
Oliva, Laura ;
Arnoldi, Elisa ;
Cornelio, Ferdinando ;
Mantegazza, Renato ;
Confalonieri, Paolo .
JOURNAL OF NEUROIMMUNOLOGY, 2006, 175 (1-2) :77-86
[3]
Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor [J].
Aricha, Revital ;
Feferman, Tali ;
Souroujon, Miriam C. ;
Fuchs, Sara .
FASEB JOURNAL, 2006, 20 (02) :374-376
[4]
Oxidative stress as a therapeutic target during muscle wasting: considering the complex interactions [J].
Arthur, Peter G. ;
Grounds, Miranda D. ;
Shavlakadze, Thea .
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2008, 11 (04) :408-416
[5]
Primary Role of Functional Ischemia, Quantitative Evidence for the Two-Hit Mechanism, and Phosphodiesterase-5 Inhibitor Therapy in Mouse Muscular Dystrophy [J].
Asai, Akihiro ;
Sahani, Nita ;
Kaneki, Masao ;
Ouchi, Yasuyoshi ;
Martyn, J. A. Jeevendra ;
Yasuhara, Shingo Egusa .
PLOS ONE, 2007, 2 (08)
[6]
Pattern of metalloprotease activity and myofiber regeneration in skeletal muscles of mdx mice [J].
Bani, Cristiane ;
Lagrota-Candido, Jussara ;
Pinheiro, Douglas Florindo ;
Correa Leite, Paulo Emllio ;
Salimena, Maria Cristina ;
Henriques-Pons, Andrea ;
Quirico-Santos, Thereza .
MUSCLE & NERVE, 2008, 37 (05) :583-592
[7]
Bcl-2 overexpression prevents calcium overload and subsequent apoptosis in dystrophic myotubes [J].
Basset, O ;
Boittin, FX ;
Cognard, C ;
Constantin, B ;
Ruegg, UT .
BIOCHEMICAL JOURNAL, 2006, 395 :267-276
[9]
BOSWELLSMITH V, 2006, BR J PHARM S1, V1, pS252
[10]
First evaluation of the potential effectiveness in muscular dystrophy of a novel chimeric compound, BN 82270, acting as calpain-inhibitor and anti-oxidant [J].
Burdi, R ;
Didonna, MP ;
Pignol, B ;
Nico, B ;
Mangieri, D ;
Rolland, JF ;
Camerino, C ;
Zallone, A ;
Ferro, P ;
Andreetta, F ;
Confalonieri, P ;
De Luca, A .
NEUROMUSCULAR DISORDERS, 2006, 16 (04) :237-248